Anlon Healthcare (NSE:AHCL) EBIT: ₹14,704 Mil (TTM As of Mar. 2026)


NSE:AHCL Anlon Healthcare Ltd NSE:AHCL
17 GF Score
Price ₹15.90
! 5 Warning Signs
View Full Analysis

What is Anlon Healthcare EBIT?

Anlon Healthcare NSE:AHCL 17 EBIT is ₹14,704 Mil as of Mar. 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

Anlon Healthcare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹14,449 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹14,704 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anlon Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 was 19.10%. Anlon Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1,983.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anlon Healthcare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 161.77%.

Anlon Healthcare  (NSE:AHCL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anlon Healthcare's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=599.988 * ( 1 - 0% )/( (0 + 3141.985)/ 1 )
=599.988/3141.985
=19.10 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3739.651 - 553.907 - ( 43.759 - max(0, 1075.657 - 3082.603+43.759))
=3141.985

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Anlon Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=57794.828/( ( (0 + max(0, 0)) + (577.136 + max(2336.831, 0)) )/ 1 )
=57794.828/( ( 0 + 2913.967 )/ 1 )
=57794.828/2913.967
=1,983.37 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1036.777 + 1131.634 + 868.487) - (553.907 + 0 + 146.16)
=2336.831

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anlon Healthcare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=14703.752/9089.513
=161.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare EBIT Related Terms

Anlon Healthcare EBIT Historical Data

* Premium members only.

The historical data trend for Anlon Healthcare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare EBIT Chart

Anlon Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
39.98 107.82 138.28 306.03 462.48

Anlon Healthcare Quarterly Data
Mar22 Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.96 164.04 133.13 121.92 14,448.71

NSE:AHCL vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anlon Healthcare EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anlon Healthcare's EV-to-EBIT falls into.


NSE:AHCL
17GF Score
Anlon Healthcare Ltd NSE:AHCL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anlon Healthcare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,704 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹14,704 Mil mean?
Anlon Healthcare (NSE:AHCL) has a EBIT of ₹14,704 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anlon Healthcare.
Is Anlon Healthcare's EBIT too high?
Anlon Healthcare's current EBIT is ₹14,704 Mil. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's EBIT compare to ZTS and UTHR?
Anlon Healthcare's EBIT of ₹14,704 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anlon Healthcare. Anlon Healthcare's current EBIT is ₹14,704 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current EBIT of ₹14,704 Mil. The current EBIT is ₹14,704 Mil. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current EBIT is ₹14,704 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anlon Healthcare Business Description

Other Exchanges 544497:India
Address Kalawad Road, 101/102, Silvercoin Complex, Opposite Crystal Mall, Rajkot, GJ, IND, 360 005
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score

Get the complete analysis for NSE:AHCL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹15.90
Price